11.40Open11.40Pre Close0 Volume278 Open Interest250.00Strike Price0.00Turnover42.51%IV-2.34%PremiumJan 17, 2025Expiry Date16.85Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8211Delta0.0159Gamma12.81Leverage Ratio-0.1876Theta-0.0472Rho-10.52Eff Leverage0.1037Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet